Concepts (279)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Bone Neoplasms | 33 | 2023 | 130 | 7.080 |
Why?
|
| Sarcoma | 15 | 2023 | 148 | 2.490 |
Why?
|
| Soft Tissue Neoplasms | 7 | 2022 | 54 | 1.740 |
Why?
|
| Bone Substitutes | 8 | 2017 | 9 | 1.570 |
Why?
|
| Giant Cell Tumor of Bone | 5 | 2022 | 16 | 1.570 |
Why?
|
| Sarcoma, Ewing | 3 | 2020 | 7 | 1.410 |
Why?
|
| Bone Transplantation | 7 | 2017 | 203 | 1.170 |
Why?
|
| Calcium Sulfate | 6 | 2012 | 8 | 1.070 |
Why?
|
| Musculoskeletal Diseases | 2 | 2015 | 44 | 0.910 |
Why?
|
| Limb Salvage | 5 | 2023 | 12 | 0.890 |
Why?
|
| Humans | 60 | 2023 | 27158 | 0.830 |
Why?
|
| Neoplasm Recurrence, Local | 7 | 2023 | 218 | 0.800 |
Why?
|
| Retrospective Studies | 27 | 2023 | 3546 | 0.790 |
Why?
|
| Leiomyosarcoma | 1 | 2021 | 23 | 0.700 |
Why?
|
| Osteosarcoma | 8 | 2021 | 40 | 0.680 |
Why?
|
| Calcium Phosphates | 2 | 2012 | 17 | 0.670 |
Why?
|
| Adult | 23 | 2022 | 7918 | 0.660 |
Why?
|
| Hip Joint | 2 | 2016 | 545 | 0.660 |
Why?
|
| Fractures, Bone | 2 | 2012 | 73 | 0.640 |
Why?
|
| Child, Preschool | 9 | 2021 | 623 | 0.630 |
Why?
|
| Synovitis, Pigmented Villonodular | 2 | 2016 | 3 | 0.620 |
Why?
|
| Adolescent | 15 | 2021 | 2179 | 0.620 |
Why?
|
| Young Adult | 12 | 2021 | 2026 | 0.620 |
Why?
|
| Tibia | 2 | 2010 | 246 | 0.590 |
Why?
|
| Child | 12 | 2021 | 1260 | 0.580 |
Why?
|
| Treatment Outcome | 16 | 2023 | 3525 | 0.560 |
Why?
|
| Chondromatosis, Synovial | 1 | 2016 | 4 | 0.530 |
Why?
|
| Middle Aged | 21 | 2021 | 9031 | 0.530 |
Why?
|
| Arthroplasty, Replacement, Knee | 5 | 2022 | 633 | 0.530 |
Why?
|
| Bone Diseases | 2 | 2017 | 24 | 0.520 |
Why?
|
| Internal Fixators | 1 | 2016 | 36 | 0.520 |
Why?
|
| Arthrodesis | 2 | 2014 | 39 | 0.510 |
Why?
|
| Male | 25 | 2021 | 14821 | 0.510 |
Why?
|
| Foot | 1 | 2016 | 44 | 0.510 |
Why?
|
| Foreign Bodies | 1 | 2016 | 26 | 0.500 |
Why?
|
| Radiotherapy | 1 | 2016 | 33 | 0.500 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 2016 | 36 | 0.500 |
Why?
|
| Acetabulum | 3 | 2016 | 228 | 0.500 |
Why?
|
| Ultrasonography, Interventional | 1 | 2016 | 71 | 0.490 |
Why?
|
| Radius | 2 | 2014 | 33 | 0.470 |
Why?
|
| Female | 22 | 2021 | 15269 | 0.460 |
Why?
|
| Tobramycin | 2 | 2005 | 8 | 0.440 |
Why?
|
| Knee Prosthesis | 2 | 2008 | 224 | 0.440 |
Why?
|
| Survival Rate | 5 | 2021 | 344 | 0.430 |
Why?
|
| Biopsy | 6 | 2023 | 200 | 0.410 |
Why?
|
| Arthralgia | 2 | 2011 | 133 | 0.400 |
Why?
|
| Anti-Bacterial Agents | 3 | 2022 | 369 | 0.390 |
Why?
|
| Cell Transformation, Neoplastic | 2 | 2010 | 33 | 0.390 |
Why?
|
| Chondrosarcoma | 4 | 2023 | 43 | 0.380 |
Why?
|
| Combined Modality Therapy | 3 | 2021 | 305 | 0.380 |
Why?
|
| Prognosis | 8 | 2023 | 804 | 0.370 |
Why?
|
| Histiocytosis, Sinus | 1 | 2011 | 4 | 0.360 |
Why?
|
| Talus | 1 | 2011 | 13 | 0.360 |
Why?
|
| Proto-Oncogene Proteins c-akt | 3 | 2017 | 60 | 0.360 |
Why?
|
| Allografts | 4 | 2021 | 216 | 0.360 |
Why?
|
| Edema | 1 | 2011 | 25 | 0.360 |
Why?
|
| Follow-Up Studies | 8 | 2022 | 1802 | 0.350 |
Why?
|
| Patellar Ligament | 1 | 2010 | 43 | 0.340 |
Why?
|
| Humerus | 3 | 2005 | 107 | 0.330 |
Why?
|
| Lung Neoplasms | 2 | 2015 | 551 | 0.330 |
Why?
|
| Prosthesis Failure | 4 | 2022 | 520 | 0.320 |
Why?
|
| Osteomyelitis | 3 | 2005 | 18 | 0.310 |
Why?
|
| Femur | 4 | 2022 | 375 | 0.310 |
Why?
|
| Bone Plates | 1 | 2008 | 45 | 0.290 |
Why?
|
| Reoperation | 6 | 2022 | 921 | 0.290 |
Why?
|
| Neoadjuvant Therapy | 5 | 2022 | 65 | 0.270 |
Why?
|
| Cisplatin | 3 | 2017 | 61 | 0.270 |
Why?
|
| Aged | 12 | 2021 | 9084 | 0.270 |
Why?
|
| Osteogenesis | 1 | 2007 | 104 | 0.260 |
Why?
|
| Arthroplasty, Replacement, Hip | 3 | 2022 | 803 | 0.250 |
Why?
|
| Orthopedic Procedures | 3 | 2004 | 308 | 0.240 |
Why?
|
| Curettage | 3 | 2022 | 9 | 0.240 |
Why?
|
| Disease-Free Survival | 3 | 2021 | 179 | 0.230 |
Why?
|
| Drug Resistance, Neoplasm | 3 | 2017 | 68 | 0.230 |
Why?
|
| Aged, 80 and over | 6 | 2021 | 4831 | 0.230 |
Why?
|
| Immunohistochemistry | 4 | 2011 | 374 | 0.230 |
Why?
|
| Transplantation, Homologous | 2 | 2004 | 279 | 0.220 |
Why?
|
| Infant | 3 | 2021 | 517 | 0.220 |
Why?
|
| Margins of Excision | 2 | 2022 | 32 | 0.220 |
Why?
|
| Pelvic Bones | 1 | 2004 | 18 | 0.220 |
Why?
|
| Lymphatic Metastasis | 2 | 2021 | 93 | 0.220 |
Why?
|
| Joint Instability | 1 | 2008 | 393 | 0.210 |
Why?
|
| Knee Joint | 2 | 2008 | 754 | 0.210 |
Why?
|
| Spinal Neoplasms | 1 | 2023 | 37 | 0.210 |
Why?
|
| Embolization, Therapeutic | 1 | 2023 | 59 | 0.200 |
Why?
|
| Kidney Neoplasms | 1 | 2023 | 79 | 0.200 |
Why?
|
| Tomography, X-Ray Computed | 4 | 2015 | 667 | 0.200 |
Why?
|
| Prostheses and Implants | 2 | 2015 | 154 | 0.200 |
Why?
|
| Neutrophils | 1 | 2023 | 100 | 0.200 |
Why?
|
| Plasma Gases | 1 | 2022 | 2 | 0.200 |
Why?
|
| Neoplasm Staging | 3 | 2022 | 368 | 0.200 |
Why?
|
| Absorbable Implants | 1 | 2002 | 27 | 0.190 |
Why?
|
| Infant, Newborn | 2 | 2021 | 562 | 0.190 |
Why?
|
| Apoptosis | 5 | 2022 | 210 | 0.190 |
Why?
|
| Vancomycin | 1 | 2002 | 52 | 0.190 |
Why?
|
| Sarcoma, Synovial | 1 | 2022 | 12 | 0.190 |
Why?
|
| Bone Cements | 3 | 2022 | 85 | 0.190 |
Why?
|
| Radiography | 5 | 2015 | 617 | 0.190 |
Why?
|
| Debridement | 2 | 2012 | 100 | 0.180 |
Why?
|
| Lymphatic Vessels | 1 | 2021 | 9 | 0.180 |
Why?
|
| Myxosarcoma | 1 | 2020 | 3 | 0.180 |
Why?
|
| Hemipelvectomy | 1 | 2020 | 2 | 0.170 |
Why?
|
| Fibrosarcoma | 1 | 2020 | 9 | 0.170 |
Why?
|
| Pelvic Neoplasms | 1 | 2020 | 9 | 0.170 |
Why?
|
| Orthopedics | 1 | 2002 | 111 | 0.170 |
Why?
|
| Hip Prosthesis | 2 | 2022 | 535 | 0.160 |
Why?
|
| Receptor, IGF Type 1 | 2 | 2017 | 21 | 0.160 |
Why?
|
| Prosthesis-Related Infections | 1 | 2022 | 184 | 0.160 |
Why?
|
| Cell Line, Tumor | 7 | 2017 | 264 | 0.160 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p27 | 2 | 2016 | 10 | 0.160 |
Why?
|
| Medically Underserved Area | 1 | 2019 | 16 | 0.150 |
Why?
|
| Dogs | 4 | 2007 | 151 | 0.150 |
Why?
|
| Antineoplastic Agents | 3 | 2017 | 202 | 0.150 |
Why?
|
| Chemoradiotherapy | 1 | 2019 | 61 | 0.150 |
Why?
|
| Medical Oncology | 1 | 2019 | 44 | 0.150 |
Why?
|
| Chemotherapy, Adjuvant | 2 | 2010 | 83 | 0.150 |
Why?
|
| Tumor Suppressor Protein p53 | 2 | 2016 | 88 | 0.150 |
Why?
|
| Health Services Accessibility | 1 | 2019 | 114 | 0.140 |
Why?
|
| Osteoarthritis | 1 | 2022 | 330 | 0.140 |
Why?
|
| Healthcare Disparities | 1 | 2019 | 86 | 0.140 |
Why?
|
| Receptors, Somatomedin | 1 | 2017 | 5 | 0.140 |
Why?
|
| Protein Kinase Inhibitors | 2 | 2017 | 55 | 0.140 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2019 | 245 | 0.140 |
Why?
|
| Imidazoles | 1 | 2017 | 62 | 0.130 |
Why?
|
| Piperazines | 1 | 2017 | 86 | 0.130 |
Why?
|
| Mechanistic Target of Rapamycin Complex 1 | 1 | 2016 | 12 | 0.130 |
Why?
|
| Synovectomy | 1 | 2016 | 5 | 0.130 |
Why?
|
| Chondroma | 3 | 2012 | 6 | 0.130 |
Why?
|
| Child Development | 1 | 2016 | 69 | 0.120 |
Why?
|
| Cohort Studies | 1 | 2021 | 1901 | 0.120 |
Why?
|
| Femoral Neoplasms | 1 | 2015 | 4 | 0.120 |
Why?
|
| Time Factors | 3 | 2022 | 1438 | 0.120 |
Why?
|
| Disease Management | 1 | 2016 | 104 | 0.120 |
Why?
|
| Prosthesis Implantation | 1 | 2015 | 27 | 0.120 |
Why?
|
| Prosthesis Design | 3 | 2022 | 483 | 0.120 |
Why?
|
| Supination | 1 | 2014 | 18 | 0.120 |
Why?
|
| Radiotherapy Dosage | 1 | 2015 | 100 | 0.120 |
Why?
|
| Ossification, Heterotopic | 1 | 2015 | 35 | 0.120 |
Why?
|
| Arthroplasty | 1 | 2016 | 151 | 0.110 |
Why?
|
| Lung | 1 | 2015 | 168 | 0.110 |
Why?
|
| Hand Strength | 1 | 2014 | 58 | 0.110 |
Why?
|
| Wrist Joint | 1 | 2014 | 59 | 0.110 |
Why?
|
| Cartilage, Articular | 2 | 2016 | 415 | 0.110 |
Why?
|
| Risk Factors | 2 | 2022 | 2334 | 0.110 |
Why?
|
| Drug Implants | 2 | 2005 | 8 | 0.110 |
Why?
|
| Protein Kinases | 1 | 2014 | 13 | 0.110 |
Why?
|
| Telomerase | 2 | 2004 | 10 | 0.110 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2011 | 1104 | 0.110 |
Why?
|
| Spinal Fusion | 1 | 2020 | 464 | 0.100 |
Why?
|
| Receptors, Notch | 1 | 2013 | 1 | 0.100 |
Why?
|
| Wnt Proteins | 1 | 2013 | 22 | 0.100 |
Why?
|
| Recovery of Function | 2 | 2012 | 297 | 0.100 |
Why?
|
| Gene Expression Regulation, Neoplastic | 3 | 2014 | 124 | 0.100 |
Why?
|
| Bone Matrix | 2 | 2003 | 19 | 0.100 |
Why?
|
| Bone Cysts | 1 | 2012 | 1 | 0.100 |
Why?
|
| Fibrous Dysplasia of Bone | 1 | 2012 | 3 | 0.100 |
Why?
|
| Injections, Intralesional | 1 | 2012 | 31 | 0.100 |
Why?
|
| Bone Regeneration | 2 | 2003 | 69 | 0.100 |
Why?
|
| beta Catenin | 1 | 2013 | 62 | 0.100 |
Why?
|
| Diagnosis, Differential | 2 | 2011 | 347 | 0.090 |
Why?
|
| Fluorodeoxyglucose F18 | 2 | 2022 | 38 | 0.090 |
Why?
|
| Positron Emission Tomography Computed Tomography | 2 | 2022 | 36 | 0.090 |
Why?
|
| Animals | 5 | 2007 | 3625 | 0.090 |
Why?
|
| Range of Motion, Articular | 1 | 2014 | 708 | 0.090 |
Why?
|
| Ankle | 1 | 2011 | 23 | 0.090 |
Why?
|
| Thoracoscopy | 1 | 2010 | 22 | 0.090 |
Why?
|
| Ilium | 1 | 2010 | 29 | 0.090 |
Why?
|
| Age Factors | 2 | 2019 | 775 | 0.080 |
Why?
|
| Proportional Hazards Models | 2 | 2021 | 350 | 0.080 |
Why?
|
| Predictive Value of Tests | 1 | 2011 | 478 | 0.080 |
Why?
|
| Chicago | 1 | 2012 | 948 | 0.080 |
Why?
|
| Survival Analysis | 1 | 2008 | 261 | 0.070 |
Why?
|
| Compressive Strength | 1 | 2007 | 18 | 0.070 |
Why?
|
| Elasticity | 1 | 2007 | 28 | 0.070 |
Why?
|
| Injections | 1 | 2007 | 42 | 0.070 |
Why?
|
| Illinois | 1 | 2008 | 250 | 0.070 |
Why?
|
| Cell Division | 3 | 2022 | 82 | 0.070 |
Why?
|
| Prospective Studies | 2 | 2023 | 1783 | 0.070 |
Why?
|
| Muscle Proteins | 1 | 2006 | 27 | 0.070 |
Why?
|
| Radiation Tolerance | 1 | 2006 | 6 | 0.070 |
Why?
|
| Glycoproteins | 1 | 2006 | 49 | 0.060 |
Why?
|
| Transcription, Genetic | 1 | 2006 | 107 | 0.060 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2006 | 29 | 0.060 |
Why?
|
| Proteins | 1 | 2006 | 64 | 0.060 |
Why?
|
| Carrier Proteins | 1 | 2006 | 98 | 0.060 |
Why?
|
| Heterocyclic Compounds, 3-Ring | 2 | 2017 | 14 | 0.060 |
Why?
|
| Phosphorylation | 2 | 2016 | 147 | 0.060 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2005 | 331 | 0.060 |
Why?
|
| Multivariate Analysis | 1 | 2005 | 331 | 0.060 |
Why?
|
| Neoplasm Invasiveness | 2 | 2021 | 93 | 0.060 |
Why?
|
| Blastomycosis | 1 | 2004 | 24 | 0.050 |
Why?
|
| Lower Extremity | 1 | 2023 | 38 | 0.050 |
Why?
|
| Biopsy, Needle | 1 | 2004 | 103 | 0.050 |
Why?
|
| Surgical Flaps | 1 | 2023 | 50 | 0.050 |
Why?
|
| Bone Demineralization Technique | 1 | 2003 | 1 | 0.050 |
Why?
|
| Lymphocyte Count | 1 | 2023 | 18 | 0.050 |
Why?
|
| Blood Loss, Surgical | 1 | 2023 | 56 | 0.050 |
Why?
|
| Mutation | 2 | 2021 | 350 | 0.050 |
Why?
|
| Tumor Microenvironment | 1 | 2023 | 21 | 0.050 |
Why?
|
| Lymphocytes | 1 | 2023 | 59 | 0.050 |
Why?
|
| Preoperative Care | 1 | 2023 | 119 | 0.050 |
Why?
|
| Exoribonucleases | 1 | 2002 | 1 | 0.050 |
Why?
|
| Genes, Tumor Suppressor | 1 | 2002 | 11 | 0.050 |
Why?
|
| Saccharomyces cerevisiae Proteins | 1 | 2002 | 14 | 0.050 |
Why?
|
| Necrosis | 1 | 2022 | 26 | 0.050 |
Why?
|
| Bone Resorption | 1 | 2003 | 83 | 0.050 |
Why?
|
| Replantation | 1 | 2022 | 10 | 0.050 |
Why?
|
| Drug Delivery Systems | 1 | 2002 | 27 | 0.050 |
Why?
|
| Signal Transduction | 2 | 2016 | 446 | 0.050 |
Why?
|
| Transplantation Immunology | 1 | 2002 | 3 | 0.050 |
Why?
|
| Arthroscopy | 1 | 2011 | 1091 | 0.050 |
Why?
|
| Printing, Three-Dimensional | 1 | 2021 | 9 | 0.050 |
Why?
|
| Forecasting | 1 | 2002 | 92 | 0.050 |
Why?
|
| Tissue and Organ Harvesting | 1 | 2002 | 19 | 0.050 |
Why?
|
| Time-to-Treatment | 1 | 2022 | 34 | 0.050 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2021 | 42 | 0.050 |
Why?
|
| Radiopharmaceuticals | 1 | 2022 | 50 | 0.050 |
Why?
|
| Positron-Emission Tomography | 1 | 2022 | 88 | 0.050 |
Why?
|
| Risk Assessment | 1 | 2004 | 628 | 0.050 |
Why?
|
| SEER Program | 1 | 2021 | 42 | 0.040 |
Why?
|
| Cartilage | 1 | 2002 | 103 | 0.040 |
Why?
|
| Neoplasm Grading | 1 | 2021 | 55 | 0.040 |
Why?
|
| DNA Damage | 2 | 2014 | 30 | 0.040 |
Why?
|
| Chronic Disease | 1 | 2002 | 425 | 0.040 |
Why?
|
| Tendons | 1 | 2002 | 221 | 0.040 |
Why?
|
| Biomechanical Phenomena | 1 | 2002 | 641 | 0.040 |
Why?
|
| Mesna | 1 | 2019 | 3 | 0.040 |
Why?
|
| Tumor Cells, Cultured | 3 | 2004 | 129 | 0.040 |
Why?
|
| Enzyme Activation | 2 | 2014 | 118 | 0.040 |
Why?
|
| Ifosfamide | 1 | 2019 | 13 | 0.040 |
Why?
|
| Organ Sparing Treatments | 1 | 2019 | 12 | 0.040 |
Why?
|
| Leg | 1 | 2019 | 50 | 0.040 |
Why?
|
| Doxorubicin | 1 | 2019 | 57 | 0.040 |
Why?
|
| Arm | 1 | 2019 | 83 | 0.040 |
Why?
|
| Drug Synergism | 1 | 2017 | 40 | 0.040 |
Why?
|
| Pyrazines | 1 | 2017 | 12 | 0.040 |
Why?
|
| Receptor Cross-Talk | 1 | 2016 | 7 | 0.030 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2015 | 177 | 0.030 |
Why?
|
| Checkpoint Kinase 1 | 1 | 2014 | 7 | 0.030 |
Why?
|
| Cell Cycle Checkpoints | 1 | 2014 | 7 | 0.030 |
Why?
|
| Gene Knockdown Techniques | 1 | 2014 | 44 | 0.030 |
Why?
|
| RNA Interference | 1 | 2014 | 38 | 0.030 |
Why?
|
| RNA, Small Interfering | 1 | 2014 | 81 | 0.030 |
Why?
|
| Hedgehog Proteins | 1 | 2013 | 7 | 0.030 |
Why?
|
| Culture Techniques | 1 | 1992 | 19 | 0.020 |
Why?
|
| Extracellular Matrix Proteins | 1 | 1992 | 46 | 0.020 |
Why?
|
| Proteoglycans | 1 | 1992 | 133 | 0.020 |
Why?
|
| Acridine Orange | 1 | 2006 | 1 | 0.020 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2006 | 54 | 0.020 |
Why?
|
| Radiation-Sensitizing Agents | 1 | 2006 | 5 | 0.020 |
Why?
|
| Gamma Rays | 1 | 2006 | 15 | 0.020 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2006 | 65 | 0.020 |
Why?
|
| Down-Regulation | 1 | 2006 | 100 | 0.020 |
Why?
|
| Cell Survival | 1 | 2006 | 119 | 0.020 |
Why?
|
| Manubrium | 1 | 2004 | 2 | 0.010 |
Why?
|
| Sternoclavicular Joint | 1 | 2004 | 6 | 0.010 |
Why?
|
| Chondrocytes | 1 | 2004 | 151 | 0.010 |
Why?
|
| Models, Animal | 1 | 2003 | 109 | 0.010 |
Why?
|
| DNA, Complementary | 1 | 2002 | 26 | 0.010 |
Why?
|
| Microscopy, Phase-Contrast | 1 | 2002 | 6 | 0.010 |
Why?
|
| Telomere | 1 | 2002 | 7 | 0.010 |
Why?
|
| Biomarkers, Tumor | 1 | 2004 | 207 | 0.010 |
Why?
|
| DNA Mutational Analysis | 1 | 2002 | 55 | 0.010 |
Why?
|
| Base Sequence | 1 | 2002 | 106 | 0.010 |
Why?
|
| DNA-Binding Proteins | 1 | 2004 | 275 | 0.010 |
Why?
|
| RNA, Messenger | 1 | 2002 | 310 | 0.010 |
Why?
|
| Disease Models, Animal | 1 | 2003 | 600 | 0.010 |
Why?
|
| Sepharose | 1 | 1992 | 4 | 0.010 |
Why?
|
| Hexuronic Acids | 1 | 1992 | 6 | 0.010 |
Why?
|
| Glucuronic Acid | 1 | 1992 | 6 | 0.010 |
Why?
|
| Alginates | 1 | 1992 | 7 | 0.010 |
Why?
|
| Keratan Sulfate | 1 | 1992 | 15 | 0.010 |
Why?
|
| Gels | 1 | 1992 | 12 | 0.010 |
Why?
|
| Lectins, C-Type | 1 | 1992 | 51 | 0.010 |
Why?
|
| Microspheres | 1 | 1992 | 25 | 0.010 |
Why?
|
| Cattle | 1 | 1992 | 124 | 0.010 |
Why?
|
| Extracellular Matrix | 1 | 1992 | 51 | 0.010 |
Why?
|
| Aggrecans | 1 | 1992 | 54 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 1992 | 524 | 0.010 |
Why?
|